Basilea Pharmaceutica AG (BSLN.S)
11 Jul 2014
|Market Cap (Mil.):||CHF1,019.53|
|Shares Outstanding (Mil.):||10.45|
ZURICH, June 25 - Shares in Swiss biotech company Basilea fell by as much as 11.5 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.
ZURICH, June 25 - Shares in Swiss biotech company Basilea fell 8 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.
June 25 - Basilea Pharmaceutica AG : * Says FDA confirmed that a potential regulatory approval of ceftobiprole in
ZURICH, June 12 - Swiss biotech company Basilea said it had started an early-stage clinical study of an antibiotic to treat infections with multi-drug resistant Gram-negative bacteria in combination with another drug.
Earnings vs. Estimates
Analyst Research Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents